[Skip to Content]
Cancer Biomarkers

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

JAMA Oncology
Published Online: April 15, 2021 Audio Author Interview 15 min 6 sec
<title>Association Between <italic>KRAS</italic> Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC</title>
Backward 15 Play Pause Forward 15
1x
0:00 / 0:00
Download MP3

Interview with Charu Aggarwal, MD, and Lova Sun, MD, authors of Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Subscribe

Subscribe on your favorite podcast source to receive future episodes of this podcast.
Learn more about this JAMA Network podcast here

Related Articles

  1. Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

See More About

Cancer Biomarkers Lung Cancer Targeted and Immune Cancer Therapy Oncology Cancer Genetics
Close
Close

Name Your Search

Save Search
Privacy Policy|Terms of Use
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue